TURP and TUEvP — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Transurethral Resection of the Prostate (TURP) is the most widely performed surgical treatment for symptomatic benign prostatic hyperplasia (BPH) and has been the <em>gold standard</em> of BPH surgery for more than 60 years. Transurethral Electrovaporization of the Prostate (TUEvP) is a modification of the same endoscopic approach that uses a high-power grooved roller electrode to simultaneously vaporise and coagulate prostatic tissue, producing haemostasis superior to standard TURP resection chips.</p><p>Benign prostatic hyperplasia — non-malignant proliferation of the stromal and glandular cells of the prostate's transitional zone — is among the most prevalent conditions in ageing men. Histological BPH is present in 50% of men aged 50 years, rising to over 80% by age 80. Clinical lower urinary tract symptoms (LUTS) attributable to BPH — urinary hesitancy, weak stream, sensation of incomplete emptying, nocturia, urgency, and urinary frequency — affect 25–30% of men over 50, with significant impact on quality of life, sleep, work productivity, and mental health.</p><p>Both TURP and TUEvP are performed entirely through the urethra using a rigid endoscope (resectoscope) — no external incisions are required. The resectoscope is passed through the urethra under direct vision into the bladder and then withdrawn to the prostatic urethra, where the obstructing adenoma (central gland tissue) is systematically removed or vaporised using electrical energy, creating a wide channel from the bladder neck to the external urethral sphincter (the <em>TURP defect</em> or <em>prostatic cavity</em>). This dramatically reduces outflow resistance and restores normal voiding.</p><p>In TURP, a wire loop electrode resects chips of prostatic tissue that are washed out from the bladder for histopathological analysis — incidentally detecting prostate cancer in approximately 7–10% of specimens. In TUEvP, a roller ball or grooved vaporising electrode converts prostatic tissue directly to vapour without producing resectable chips, reducing irrigation fluid absorption and haemorrhage at the cost of not having tissue for histology.</p><p>The introduction of <strong>bipolar TURP</strong> — which uses a bipolar electrical circuit confined within the resectoscope, enabling use of isotonic saline irrigation instead of hypotonic glycine solution — has revolutionised the safety profile of TURP by virtually eliminating TUR syndrome (dilutional hyponatraemia from irrigation fluid absorption), the most feared complication of monopolar TURP. Bipolar TURP is now the standard of care in most high-volume urology centres worldwide.</p>

<p>TURP and TUEvP are primarily employed for symptomatic benign prostatic hyperplasia but address a broader spectrum of lower urinary tract conditions arising from prostatic obstruction.</p><ul><li><strong>Benign Prostatic Hyperplasia (BPH) with Moderate-to-Severe LUTS:</strong> The primary indication. Patients with moderate-to-severe lower urinary tract symptoms (IPSS score ≥8) that significantly impair quality of life and have not responded to medical therapy are candidates for surgical intervention. TURP achieves a 70–80% reduction in IPSS score and 100–150% improvement in maximum urinary flow rate (Qmax) in published series — outcomes far superior to medical therapy alone.</li><li><strong>Acute Urinary Retention (AUR) Failing Trial Without Catheter (TWOC):</strong> Men who present with acute urinary retention attributable to BPH and fail one or more attempts at catheter removal (trial without catheter after alpha-blocker therapy) require definitive surgical decompression. TURP is the standard definitive treatment in this setting, eliminating the need for long-term catheterisation.</li><li><strong>Recurrent Urinary Tract Infections (UTIs) Secondary to BPH:</strong> Chronic urinary stasis from incomplete bladder emptying (elevated post-void residual volume) creates a favourable environment for bacterial colonisation and recurrent UTIs. Surgical relief of obstruction resolves the underlying stasis and dramatically reduces UTI frequency.</li><li><strong>Bladder Stone Formation Secondary to BPH:</strong> Urinary stasis promotes crystallisation and bladder stone formation. TURP is performed concurrently with or after cystolithalopaxy (endoscopic stone fragmentation) to eliminate the obstructive cause and prevent recurrent stone formation.</li><li><strong>Recurrent Haematuria from BPH:</strong> Bleeding from the highly vascular BPH adenoma causing recurrent significant haematuria, where medical management with 5-alpha-reductase inhibitors has failed or is insufficient, is an indication for TURP to coagulate and remove the bleeding tissue.</li><li><strong>Upper Urinary Tract Obstruction / Renal Impairment from BPH:</strong> Severe, long-standing BPH can produce bilateral ureteric obstruction from trigonal hypertrophy and elevated bladder pressure, causing hydronephrosis and chronic kidney disease. TURP is urgently indicated to relieve this obstructive uropathy before renal damage becomes irreversible.</li><li><strong>Bladder Diverticulum Secondary to BPH:</strong> High-pressure voiding against a prostatic obstruction can produce bladder diverticula. TURP relieves the underlying obstruction; large symptomatic diverticula may additionally require surgical repair.</li></ul>

<p>TURP and TUEvP are recommended for men with symptomatic BPH who meet clinical criteria indicating surgical intervention is appropriate. Eligibility is established through standardised symptom scoring, urodynamic assessment, and assessment of absolute and relative indications.</p><p><strong>Absolute Indications (Surgery Required):</strong></p><ul><li>Urinary retention refractory to medical management or failing trial without catheter</li><li>Recurrent UTIs or sepsis attributable to urinary stasis from BPH</li><li>Renal impairment or hydronephrosis caused by bladder outlet obstruction</li><li>Bladder stones resulting from urinary stasis</li><li>Recurrent gross haematuria from BPH unresponsive to 5-alpha-reductase inhibitors</li></ul><p><strong>Relative Indications (Surgery after Failed Medical Therapy):</strong></p><ul><li>IPSS (International Prostate Symptom Score) score ≥8, indicating moderate-to-severe LUTS that substantially impair quality of life</li><li>Failure of or intolerance to medical therapy: alpha-blockers (tamsulosin, silodosin, alfuzosin), 5-alpha-reductase inhibitors (finasteride, dutasteride), or combination therapy</li><li>Maximum urinary flow rate (Qmax) below 10 mL/second on uroflowmetry</li><li>Elevated post-void residual (PVR) volume above 150–200 mL on bladder ultrasound</li><li>Patient preference for definitive surgical treatment over long-term daily medication</li></ul><p><strong>Prostate Size Considerations:</strong> TURP is best suited for prostate glands of 30–80 mL volume. For glands above 80–100 mL, endoscopic enucleation techniques — holmium laser enucleation of the prostate (HoLEP) or thulium laser enucleation (ThuLEP) — or open/robotic simple prostatectomy are preferred. TUEvP has similar size constraints to TURP.</p><p><strong>Medical Fitness Assessment:</strong> Pre-operative workup includes: midstream urine culture (treating infection before surgery), serum PSA (to exclude prostate cancer and serve as a baseline), renal function tests (eGFR, creatinine), full blood count, coagulation profile, and ECG. Antiplatelet agents (aspirin, clopidogrel) and anticoagulants (warfarin, DOACs) require peri-operative management — typically stopping 5–10 days before surgery in consultation with the prescribing physician and haematologist.</p><p><strong>Exclusion of Prostate Cancer:</strong> Significantly elevated PSA (above 4 ng/mL, or 3 ng/mL with a suspicious digital rectal examination) warrants multi-parametric MRI and prostate biopsy before TURP to exclude prostate cancer that would alter the management plan.</p><p><strong>Fertility Considerations:</strong> Retrograde ejaculation (semen entering the bladder rather than being expelled anteriorly at orgasm) occurs in 65–90% of patients after TURP and is essentially a permanent consequence of damaging the bladder neck smooth muscle. Men wishing to preserve biological paternity should discuss sperm banking before TURP and explore alternative procedures with lower retrograde ejaculation rates (UroLift, Rezum, PAE).</p>

<p>The management of BPH requiring surgical intervention encompasses TURP and its technological refinements, TUEvP, and a range of alternative energy-based endoscopic techniques. The optimal choice depends on prostate size, surgeon expertise, equipment availability, and patient-specific factors.</p><p><strong>1. Monopolar TURP (M-TURP) — The Historical Gold Standard:</strong> The original TURP technique uses a monopolar resectoscope with a wire cutting loop energised by diathermy current. Irrigating fluid (1.5% glycine, sorbitol, or mannitol — non-electrolyte solutions) is used to maintain visibility. The surgeon systematically resects the obstructing adenoma lobe by lobe (lateral lobes, middle lobe, apical tissue) in sequential passes of the cutting loop, creating chips of prostatic tissue that are washed into the bladder and evacuated. Operative time is 45–90 minutes depending on prostate size. Monopolar TURP carries a risk of TUR syndrome from absorption of hypotonic irrigant.</p><p><strong>2. Bipolar TURP (B-TURP) — Current Preferred Standard:</strong> Uses a bipolar resectoscope in which the active and return electrode are both contained within the instrument, allowing use of isotonic normal saline (0.9% NaCl) as irrigation fluid. This eliminates TUR syndrome (as saline absorption does not cause hyponatraemia), enables longer resection times without time pressure, and achieves equivalent or slightly superior haemostasis compared to monopolar TURP. Meta-analyses and randomised trials confirm that B-TURP provides equivalent functional outcomes to M-TURP with a significantly improved safety profile. Bipolar TURP has become the standard of care in most high-volume centres.</p><p><strong>3. Transurethral Electrovaporization of the Prostate (TUEvP):</strong> Uses a grooved roller ball or vaporising electrode instead of a cutting loop. The high-power electrode (up to 200W) simultaneously vaporises tissue to steam and coagulates the underlying tissue. This produces a desiccated, coagulated channel rather than resectable chips, with significantly better intraoperative haemostasis than standard resection — an advantage for patients on anticoagulants or with bleeding diatheses. Disadvantages: no tissue chips for histological analysis (cannot exclude prostate cancer); the desiccated tissue sloughs over 2–4 weeks post-operatively, causing a secondary postoperative haemorrhage risk in 5–10% of patients; slightly slower tissue removal than TURP.</p><p><strong>4. Combined TUEvP-TURP (TUVRP):</strong> Many urologists use a combined technique, alternating vaporisation with resection, achieving both superior haemostasis and preservation of tissue chips for histology.</p><p><strong>5. Bipolar Plasma Vaporisation (BPVP):</strong> A bipolar version of TUEvP using saline irrigation to eliminate TUR syndrome risk while maintaining the haemostatic advantages of vaporisation. Increasingly available and gaining acceptance, particularly for medium-sized prostates.</p><p><strong>Peri-operative Management:</strong> All variants are performed under spinal or general anaesthesia. A three-way urethral catheter (22–24 Fr) is placed at the end of surgery to allow continuous bladder irrigation to prevent clot retention. The catheter is typically removed at 24–48 hours if the urine has cleared, and a successful voiding trial is confirmed before discharge. Prophylactic antibiotics (gentamicin, cephalosporin) are administered at induction and for 24 hours post-operatively according to local protocols.</p>

<p>TURP and TUEvP have an unrivalled evidence base accumulated over six decades of worldwide clinical use, establishing them as the most reliably effective surgical treatments for symptomatic BPH.</p><ul><li><strong>Dramatic and Sustained Symptom Improvement:</strong> TURP achieves a 70–80% reduction in International Prostate Symptom Score (IPSS), a 100–150% improvement in maximum urinary flow rate (Qmax from approximately 8 mL/s to 18–22 mL/s), and a significant reduction in post-void residual volume. These improvements are sustained over long periods — 10-year re-treatment rates with TURP are approximately 5%, compared to 20–30% for minimally invasive alternatives.</li><li><strong>Rapid Resolution of Urinary Retention:</strong> For men in urinary retention who have been catheter-dependent, TURP eliminates the obstruction and restores independent voiding in 80–90% of cases, eliminating the risk, discomfort, and infection associated with long-term catheterisation.</li><li><strong>Incidental Prostate Cancer Detection:</strong> Histopathological analysis of TURP chips detects incidental prostate cancer in approximately 7–10% of specimens — enabling early diagnosis and timely oncological management that would otherwise be delayed until PSA-triggered biopsy.</li><li><strong>Quality of Life Restoration:</strong> The profound impact of LUTS on sleep (nocturia), sexual function, social activity, and psychological wellbeing is dramatically relieved in the majority of patients. Multiple quality-of-life studies demonstrate significant improvements in SF-36, IPSS quality-of-life domain, and validated disease-specific questionnaires after TURP.</li><li><strong>Prevention of Complications:</strong> TURP prevents the progression of BPH to irreversible complications including bilateral hydronephrosis, chronic renal failure, and large bladder diverticula that become progressively harder to manage as the disease advances untreated.</li><li><strong>No External Incisions:</strong> The entirely transurethral approach leaves no abdominal incision, avoids laparotomy-related complications (wound infection, hernia), and results in significantly faster recovery than open prostatectomy.</li><li><strong>Cost-Effective Long-Term Option:</strong> While TURP has higher upfront cost than medical therapy, its durable efficacy (low re-treatment rate over 10 years) makes it cost-effective when calculated over a lifetime, particularly compared to continuous daily medication (alpha-blockers + 5-ARIs) taken indefinitely.</li></ul>

<p>TURP is a major endoscopic procedure with a well-characterised complication profile. The adoption of bipolar technology has substantially reduced the most serious complications compared to monopolar TURP, but patients should be counselled about all relevant risks during pre-operative informed consent.</p><ul><li><strong>Retrograde Ejaculation:</strong> The most common significant adverse outcome — occurring in 65–90% of patients after TURP. The resection of the bladder neck smooth muscle prevents normal anterograde ejaculation; at orgasm, semen flows retrograde into the bladder and is excreted with the subsequent urine. Retrograde ejaculation does not affect erectile function, libido, sensation of orgasm, or urinary continence, but it renders patients anejaculatory and effectively infertile by conventional intercourse. Men wishing to preserve biological paternity should bank sperm before TURP. This consequence is permanent and essentially universal — it is an expected anatomical consequence of the procedure, not a complication.</li><li><strong>TUR Syndrome (Monopolar TURP Only):</strong> Historically the most feared serious complication of monopolar TURP — caused by absorption of large volumes of hypotonic irrigation fluid through opened prostatic venous sinuses during resection, leading to dilutional hyponatraemia, volume overload, cerebral oedema, and cardiovascular compromise. Symptoms: confusion, nausea, bradycardia, hypertension. Management: immediate cessation of irrigation, intravenous furosemide, and in severe cases hypertonic (3%) saline. TUR syndrome is virtually eliminated by bipolar TURP with saline irrigation — one of the strongest arguments for bipolar over monopolar TURP.</li><li><strong>Haemorrhage:</strong> Intraoperative bleeding requiring transfusion occurs in 2–5% of cases. Post-operative secondary haemorrhage — typically from slough of the prostatic cavity at 7–14 days, or from early catheter removal before haemostasis is complete — may require catheter reinsertion and bladder irrigation. TUEvP produces superior intraoperative haemostasis compared to TURP but carries a slightly higher secondary haemorrhage rate due to slough of necrotic tissue.</li><li><strong>Urinary Incontinence:</strong> Transient stress urinary incontinence occurs in 5–10% of patients and usually resolves within 3–6 months as pelvic floor muscle function improves. Permanent stress urinary incontinence from damage to the external urethral sphincter occurs in less than 1% of cases when performed by experienced surgeons but can be devastating — requiring treatment with a male urethral sling or artificial urinary sphincter.</li><li><strong>Urethral Stricture and Bladder Neck Contracture:</strong> Scar tissue formation at the resectoscope entry site (urethral stricture) or at the bladder neck (bladder neck contracture) occurs in 3–5% of patients, causing recurrent obstructive voiding symptoms requiring endoscopic dilation or incision.</li><li><strong>Erectile Dysfunction:</strong> New post-operative erectile dysfunction occurs in approximately 5–10% of patients who had normal preoperative erectile function, possibly from thermal or electrical damage to the cavernous nerves coursing posterolateral to the prostate. The risk is lower than in radical prostatectomy for prostate cancer.</li><li><strong>Urinary Tract Infection:</strong> Bacteriuria and symptomatic UTI in the post-operative period occur in 10–15% of patients. Prophylactic perioperative antibiotics and catheter removal as early as safely possible reduce this risk.</li></ul>

<p>Structured post-operative follow-up after TURP or TUEvP monitors voiding function recovery, detects complications, and assesses long-term durability of surgical outcome.</p><p><strong>Immediate Post-Operative Period (Days 1–3):</strong> Patients are admitted post-procedure for catheter management and bladder irrigation. The three-way catheter enables continuous bladder irrigation to prevent clot retention during the period of maximal prostatic bleeding. Once irrigation fluid clears to light pink or clear (typically 12–24 hours post-operatively), the irrigation rate is reduced. The catheter is removed at 24–48 hours when urine is sufficiently clear, subject to a voiding trial — the patient voids spontaneously and post-void residual is checked by bladder scan. If voiding is unsuccessful, the catheter is replaced for a further 24–48 hours.</p><p><strong>Discharge Instructions:</strong> Patients are counselled on expected post-discharge symptoms including terminal haematuria (blood at the end of urine stream) and mild dysuria for 4–6 weeks during prostatic cavity healing and tissue sloughing. Instructions include:</p><ul><li>Maintain high fluid intake (2–3 litres daily) to dilute urine and reduce irritative symptoms</li><li>Avoid strenuous physical activity, heavy lifting, and sexual intercourse for 4–6 weeks</li><li>Avoid constipation (straining increases bleeding risk) with dietary fibre and laxatives</li><li>Contact the urology team immediately if frank haematuria with clots, inability to void, or fever develops</li><li>Complete the prescribed course of oral antibiotics and alpha-blockers for bladder neck relaxation during the healing phase</li></ul><p><strong>First Outpatient Review (4–6 Weeks):</strong> Symptom assessment using the IPSS questionnaire, uroflowmetry to document improvement in maximum flow rate (Qmax), and post-void residual volume measurement by bladder ultrasound. Urine dipstick and culture if symptoms of UTI. PSA measurement at 3 months post-TURP (as a new, significantly lower post-TURP PSA baseline).</p><p><strong>Six-Month Review:</strong> Formal assessment of functional outcome — IPSS, Qmax, PVR, and quality-of-life domain — compared to pre-operative baseline. Histopathology report of resected chips is reviewed with the patient. Incidentally detected prostate cancer found in TURP chips requires urological oncology referral and staging workup.</p><p><strong>Annual PSA Surveillance:</strong> Post-TURP PSA falls to approximately 50% of pre-operative values due to removal of adenoma tissue. Annual PSA monitoring continues for prostate cancer surveillance in the remaining prostatic tissue (TURP removes only the central adenoma, not the peripheral zone where most prostate cancers arise).</p><p><strong>Long-Term Follow-Up:</strong> Re-treatment rates for BPH after TURP are approximately 5% at 10 years — primarily due to adenoma regrowth in the remaining peripheral zone or bladder neck contracture. Patients with recurrent LUTS are investigated with flow studies and cystoscopy before re-treatment decision.</p>

<p>The cost of TURP and TUEvP varies significantly by country, hospital type, and whether bipolar or monopolar equipment is used. Understanding the cost structure helps patients make informed choices between competing treatment options.</p><p><strong>Procedure Costs by Country (Approximate):</strong></p><ul><li><em>India (Private Hospitals):</em> INR 60,000–150,000 (USD 720–1,800) for bipolar TURP including surgical fee, anaesthesia, hospital stay, catheter, and routine post-operative care. Costs vary by city — major metropolises (Delhi, Mumbai, Chennai, Bengaluru) are at the higher end; tier-2 cities are lower. Government hospitals offer TURP at substantially subsidised rates or free under public health schemes.</li><li><em>Thailand / Malaysia / Singapore:</em> USD 3,000–8,000 at JCI-accredited private hospitals — a common destination for medical tourists from South Asia, the Middle East, and Africa seeking high-quality urology services.</li><li><em>Turkey / Eastern Europe:</em> USD 2,500–6,000 in private urology centres — popular for European patients seeking cost-effective care.</li><li><em>United Kingdom (NHS):</em> Free at the point of care for eligible patients; NHS waiting times apply. Private TURP in the UK: GBP 4,000–8,000.</li><li><em>United States:</em> USD 10,000–30,000 for the total episode of care including surgeon fee, anaesthesiologist, hospital facility, and supplies — substantially reduced for patients with Medicare or private insurance with inpatient surgical coverage.</li></ul><p><strong>Bipolar vs. Monopolar Cost Differential:</strong> Bipolar TURP equipment (resectoscope, generator, disposable electrodes) adds USD 200–500 in disposable costs compared to monopolar TURP but may reduce overall hospitalisation costs by shortening procedure time and reducing irrigation-related complications.</p><p><strong>Pre-operative Investigation Costs:</strong> Uroflowmetry (USD 50–100), PSA blood test (USD 20–60), transrectal ultrasound for prostate volume measurement (USD 100–250), urodynamic study if indicated (USD 200–500), and pre-anaesthetic blood tests add to total care costs.</p><p><strong>Comparison with Medical Therapy (Long-Term):</strong> Combination medical therapy (tamsulosin + dutasteride) costs approximately USD 400–800 per year in India and USD 1,500–3,000 per year in high-income countries when taken continuously for life. Over a 10-year horizon, TURP — with a single upfront procedure and low re-treatment rate — may be more cost-effective than decades of daily medication, particularly in younger men expected to live for 20–30 years.</p><p><strong>Insurance Coverage:</strong> TURP for documented BPH with urinary obstruction is covered by most health insurance policies in India, Gulf countries, and high-income countries as a medically necessary procedure. Pre-authorisation documentation of IPSS score, uroflowmetry results, and failed medical therapy is typically required.</p>

<p>A growing number of medical, minimally invasive, and surgical alternatives to TURP and TUEvP are now available for BPH. The optimal choice depends on prostate size, symptom severity, patient age and fertility considerations, comorbidity, and patient preference after informed discussion.</p><p><strong>Medical Therapy (First-Line for Most Patients):</strong></p><ul><li><em>Alpha-1 adrenergic blockers:</em> Tamsulosin, silodosin, alfuzosin, doxazosin — relax smooth muscle in the prostate and bladder neck, improving urinary flow within 1–2 weeks. Most commonly prescribed first-line drugs for LUTS-BPH. Side effects include retrograde ejaculation (tamsulosin, silodosin), postural hypotension, and dizziness.</li><li><em>5-alpha-reductase inhibitors (5-ARIs):</em> Finasteride and dutasteride block conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume by 20–30% over 3–6 months. Most effective for larger prostates (>40 mL). Combination alpha-blocker + 5-ARI is more effective than either drug alone for moderate-large BPH.</li><li><em>Phosphodiesterase-5 inhibitors:</em> Tadalafil 5 mg daily is approved for BPH-LUTS, providing bladder and prostatic smooth muscle relaxation while treating concurrent erectile dysfunction.</li></ul><p><strong>Surgical Alternatives to TURP:</strong></p><ul><li><em>Holmium Laser Enucleation of the Prostate (HoLEP):</em> The surgical gold standard for large prostates (>80–100 mL) and increasingly for all sizes. Uses holmium laser to enucleate the entire adenoma in anatomical planes, offering outcomes superior to TURP with lower bleeding risk, no TUR syndrome, and applicable to any prostate size regardless of anticoagulation. Limited availability due to equipment cost and steep learning curve.</li><li><em>Thulium Laser Enucleation (ThuLEP) / Thulium Fiber Laser Vaporisation:</em> Emerging equivalent to HoLEP with potentially shorter learning curve.</li><li><em>GreenLight Laser (PVP — Photoselective Vaporization of the Prostate):</em> 532 nm KTP/LBO laser vaporises prostatic tissue. Excellent haemostasis makes it suitable for patients on anticoagulants. No tissue for histology. Effective for moderate-sized prostates with outcomes approaching TURP.</li><li><em>Open / Robotic Simple Prostatectomy:</em> For very large prostates (>100–150 mL) where endoscopic enucleation is not available. The most invasive option with longest recovery but treats any prostate size definitively.</li></ul><p><strong>Minimally Invasive Surgical Therapies (MISTs) — Preserving Ejaculatory Function:</strong></p><ul><li><em>Prostatic Urethral Lift (UroLift):</em> Implants permanent sutures to hold the lateral prostatic lobes apart, mechanically opening the urethra. Ejaculatory function is preserved in 98% of patients — the strongest differentiator from TURP. Suitable for prostates 30–80 mL without a prominent middle lobe. Less durable than TURP (re-treatment rate 13% at 5 years). Performed under local or light general anaesthesia.</li><li><em>Rezum Water Vapour Therapy:</em> Convective radiofrequency-generated water vapour is injected into the prostatic adenoma via a transurethral cystoscope, causing cellular necrosis. Preserves ejaculation in most cases. Effective for moderate BPH including middle lobe hypertrophy. Re-treatment rate approximately 5% at 5 years.</li><li><em>Prostatic Artery Embolisation (PAE):</em> An interventional radiology procedure in which microcatheters are used to embolise the prostatic arterial supply, causing ischemic reduction in prostate volume. Performed under local anaesthesia. Preserves ejaculatory function. Re-treatment rates higher than TURP at 5–10 years. Best evidence for large-gland BPH (>80 mL) where surgical risk is elevated.</li></ul>